November 8, 2017 / 2:10 PM / 9 days ago

BRIEF-Zealand Pharma Q3 operating loss at DKK 38.2 mln ​

Nov 8 (Reuters) - ZEALAND PHARMA A/S:

* ‍MAINTAINS ITS REVENUE GUIDANCE OF A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI.​

* ‍REVISED FINANCIAL GUIDANCE FOR 2017​

* ‍NET OPERATING EXPENSES IN 2017 ARE EXPECTED TO BE WITHIN RANGE OF DKK 375-385 MILLION, 4-6 % LOWER THAN PREVIOUSLY GUIDED​

* ‍NET OPERATING EXPENSES IN 2017 ARE EXPECTED TO BE WITHIN RANGE OF DKK 375-385 MILLION, 4-6 % LOWER THAN PREVIOUSLY GUIDED (DKK 390-410 MILLION).​

* Q3 REVENUE DKK 40.1‍​ MILLION VERSUS DKK 39.6 MILLION YEAR AGO

* 2017 ‍OPERATING LOSS BEFORE ROYALTY INCOME/EXPENSES HAS BEEN REDUCED FROM DKK 290-310 MILLION TO DKK 275-285 MILLION​

* ‍FOR 2017, ZEALAND MAINTAINS ITS REVENUE GUIDANCE OF A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI​

* Q3 OPERATING LOSS DKK 38.2 ‍​ MILLION VERSUS LOSS DKK 21.2 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below